User menu

The HUMTICK study: protocol for a prospective cohort study on post-treatment Lyme disease syndrome and the disease and cost burden of Lyme borreliosis in Belgium.

Bibliographic reference Geebelen, Laurence ; Lernout, Tinne ; Kabamba-Mukadi, Benoît ; Saegeman, Veroniek ; Sprong, Hein ; et. al. The HUMTICK study: protocol for a prospective cohort study on post-treatment Lyme disease syndrome and the disease and cost burden of Lyme borreliosis in Belgium.. In: Archives of Public Health, Vol. 75, p. 42 [1-8]
Permanent URL
  1. Stanek Gerold, Wormser Gary P, Gray Jeremy, Strle Franc, Lyme borreliosis, 10.1016/s0140-6736(11)60103-7
  2. Wormser Gary P., Dattwyler Raymond J., Shapiro Eugene D., Halperin John J., Steere Allen C., Klempner Mark S., Krause Peter J., Bakken Johan S., Strle Franc, Stanek Gerold, Bockenstedt Linda, Fish Durland, Dumler J. Stephen, Nadelman Robert B., The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America, 10.1086/508667
  3. Hofhuis Agnetha, Herremans Tineke, Notermans Daan W., Sprong Hein, Fonville Manoj, van der Giessen Joke W. B., van Pelt Wilfrid, A Prospective Study among Patients Presenting at the General Practitioner with a Tick Bite or Erythema Migrans in the Netherlands, 10.1371/journal.pone.0064361
  4. Huegli Delphine, Moret Jacqueline, Rais Olivier, Moosmann Yves, Erard Philippe, Malinverni Raffaele, Gern Lise, Prospective study on the incidence of infection by Borrelia burgdorferi sensu lato after a tick bite in a highly endemic area of Switzerland, 10.1016/j.ttbdis.2011.05.002
  5. Wilhelmsson Peter, Fryland Linda, Lindblom Pontus, Sjöwall Johanna, Ahlm Clas, Berglund Johan, Haglund Mats, Henningsson Anna J., Nolskog Peter, Nordberg Marika, Nyberg Clara, Ornstein Katharina, Nyman Dag, Ekerfelt Christina, Forsberg Pia, Lindgren Per-Eric, A prospective study on the incidence of Borrelia burgdorferi sensu lato infection after a tick bite in Sweden and on the Åland Islands, Finland (2008–2009), 10.1016/j.ttbdis.2015.08.009
  6. LETRILLIART L., RAGON B., HANSLIK T., FLAHAULT A., Lyme disease in France: a primary care-based prospective study, 10.1017/s0950268805004413
  7. Rizzoli A, Hauffe H, Carpi G, Vourc HG, Neteler M, Rosa R. Lyme borreliosis in Europe. Euro Surveill. 2011;16
  8. Berglund Johan, Eitrem Rickard, Ornstein Katharina, Lindberg Anders, Ringnér Åke, Elmrud Henrik, Carlsson Mikael, Runehagen Arne, Svanborg Catarina, Norrby Ragnar, An Epidemiologic Study of Lyme Disease in Southern Sweden, 10.1056/nejm199511163332004
  9. Wilking Hendrik, Stark Klaus, Trends in surveillance data of human Lyme borreliosis from six federal states in eastern Germany, 2009–2012, 10.1016/j.ttbdis.2013.10.010
  10. Hofhuis Agnetha, Harms Margriet, Bennema Sita, van den Wijngaard Cees C, van Pelt Wilfrid, Physician reported incidence of early and late Lyme borreliosis, 10.1186/s13071-015-0777-6
  11. Vandenesch A, Turbelin C, Couturier E, Arena C, Jaulhac B, Ferquel E, Choumet V, Saugeon C, Coffinieres E, Blanchon T, Vaillant V, Hanslik T, Incidence and hospitalisation rates of Lyme borreliosis, France, 2004 to 2012, 10.2807/1560-7917.es2014.19.34.20883
  12. Stanek G., Fingerle V., Hunfeld K.-P., Jaulhac B., Kaiser R., Krause A., Kristoferitsch W., O'Connell S., Ornstein K., Strle F., Gray J., Lyme borreliosis: Clinical case definitions for diagnosis and management in Europe, 10.1111/j.1469-0691.2010.03175.x
  13. Aucott John N., Crowder Lauren A., Kortte Kathleen B., Development of a foundation for a case definition of post-treatment Lyme disease syndrome, 10.1016/j.ijid.2013.01.008
  14. Aucott John N., Rebman Alison W., Crowder Lauren A., Kortte Kathleen B., Post-treatment Lyme disease syndrome symptomatology and the impact on life functioning: is there something here?, 10.1007/s11136-012-0126-6
  15. Aucott John N., Posttreatment Lyme Disease Syndrome, 10.1016/j.idc.2015.02.012
  16. Koedel Uwe, Fingerle Volker, Pfister Hans-Walter, Lyme neuroborreliosis—epidemiology, diagnosis and management, 10.1038/nrneurol.2015.121
  17. Marques Adriana, Chronic Lyme Disease: A Review, 10.1016/j.idc.2007.12.011
  18. Wormser Gary P., Ramanathan Roshan, Nowakowski John, McKenna Donna, Holmgren Diane, Visintainer Paul, Dornbush Rhea, Singh Brij, Nadelman Robert B., Duration of Antibiotic Therapy for Early Lyme Disease : A Randomized, Double-Blind, Placebo-Controlled Trial, 10.7326/0003-4819-138-9-200305060-00005
  19. Cerar Daša, Cerar Tjaša, Ružić-Sabljić Eva, Wormser Gary P., Strle Franc, Subjective Symptoms after Treatment of Early Lyme Disease, 10.1016/j.amjmed.2009.05.011
  20. Cairns Victoria, Godwin Jon, Post-Lyme borreliosis syndrome: a meta-analysis of reported symptoms, 10.1093/ije/dyi129
  21. Adrion Emily R., Aucott John, Lemke Klaus W., Weiner Jonathan P., Health Care Costs, Utilization and Patterns of Care following Lyme Disease, 10.1371/journal.pone.0116767
  22. Seltzer Elyse G., Long-term Outcomes of Persons With Lyme Disease, 10.1001/jama.283.5.609
  23. Aucott John N., Soloski Mark J., Rebman Alison W., Crowder Lauren A., Lahey Lauren J., Wagner Catriona A., Robinson William H., Bechtold Kathleen T., CCL19 as a Chemokine Risk Factor for Posttreatment Lyme Disease Syndrome: a Prospective Clinical Cohort Study, 10.1128/cvi.00071-16
  24. Nowakowski John, Nadelman Robert B, Sell Rebecca, McKenna Donna, Cavaliere L.Frank, Holmgren Diane, Gaidici Adriana, Wormser Gary P, Long-term follow-up of patients with culture-confirmed lyme disease, 10.1016/s0002-9343(03)00308-5
  25. Eikeland R., Mygland Å., Herlofson K., Ljøstad U., Risk factors for a non-favorable outcome after treated European neuroborreliosis, 10.1111/j.1600-0404.2012.01690.x
  26. Krause Peter J., Concurrent Lyme Disease and Babesiosis : Evidence for Increased Severity and Duration of Illness, 10.1001/jama.1996.03530450047031
  27. Cochez C., Heyman P., Heylen D., Fonville M., Hengeveld P., Takken W., Simons L., Sprong H., The Presence ofBorrelia miyamotoi, A Relapsing Fever Spirochaete, in QuestingIxodes ricinusin Belgium and in The Netherlands, 10.1111/zph.12154
  28. Jahfari Setareh, Fonville Manoj, Hengeveld Paul, Reusken Chantal, Scholte Ernst-Jan, Takken Willem, Heyman Paul, Medlock Jolyon M, Heylen Dieter, Kleve Jenny, Sprong Hein, Prevalence of Neoehrlichia mikurensis in ticks and rodents from North-west Europe, 10.1186/1756-3305-5-74
  29. Claerebout Edwin, Losson Bertrand, Cochez Christel, Casaert Stijn, Dalemans Anne-Catherine, De Cat Ann, Madder Maxime, Saegerman Claude, Heyman Paul, Lempereur Laetitia, Ticks and associated pathogens collected from dogs and cats in Belgium, 10.1186/1756-3305-6-183
  30. Borgermans Liesbeth, Goderis Geert, Vandevoorde Jan, Devroey Dirk, Relevance of Chronic Lyme Disease to Family Medicine as a Complex Multidimensional Chronic Disease Construct: A Systematic Review, 10.1155/2014/138016
  31. Berghoff Walter, Chronic Lyme Disease and Co-infections: Differential Diagnosis, 10.2174/1874205x01206010158
  32. Lantos Paul M., Wormser Gary P., Chronic Coinfections in Patients Diagnosed with Chronic Lyme Disease: A Systematic Review, 10.1016/j.amjmed.2014.05.036
  33. Lantos Paul M., Chronic Lyme Disease, 10.1016/j.idc.2015.02.006
  34. Wang T. J., Liang M. H., Sangha O., Phillips C. B., Lew R. A., Wright E. A., Berardi V., Fossel A. H., Shadick N. A., Coexposure to Borrelia burgdorferi and Babesia microti Does Not Worsen the Long-Term Outcome of Lyme Disease, 10.1086/317465
  35. Ramsey Alan H., Outcomes of Treated Human Granulocytic Ehrlichiosis Cases, 10.3201/eid0804.010222
  36. Bleyenheuft Corinne, Lernout Tinne, Berger Nicolas, Rebolledo Javiera, Leroy Mathias, Robert Annie, Quoilin Sophie, Epidemiological situation of Lyme borreliosis in Belgium, 2003 to 2012, 10.1186/s13690-015-0079-7
  37. Vanthomme K., Bossuyt N., Boffin N., Casteren V., Incidence and management of presumption of Lyme borreliosis in Belgium: recent data from the sentinel network of general practitioners, 10.1007/s10096-012-1580-3
  38. Lantos Paul M, Chronic Lyme disease: the controversies and the science, 10.1586/eri.11.63
  39. Ware John E., Sherbourne Cathy Donald, The MOS 36-ltem Short-Form Health Survey (SF-36) : I. Conceptual Framework and Item Selection, 10.1097/00005650-199206000-00002
  40. Aaronson Neil K., Muller Martin, Cohen Peter D.A., Essink-Bot Marie-Louise, Fekkes Minne, Sanderman Robbert, Sprangers Mirjam A.G., te Velde Adrienne, Verrips Erik, Translation, Validation, and Norming of the Dutch Language Version of the SF-36 Health Survey in Community and Chronic Disease Populations, 10.1016/s0895-4356(98)00097-3
  41. Razavi Darius, Gandek Barbara, Testing Dutch and French Translations of the SF-36 Health Survey among Belgian Angina Patients, 10.1016/s0895-4356(98)00089-4
  42. Vom Hofe A, Mainemarre G, Vannier L-C. Sensitivity to everyday failures and cognitive inhibition: are they related? European Review of Applied Psychology / Revue Européenne de Psychologie Appliquée. 1998;48:49–56.
  43. Broadbent D. E., Cooper P. F., FitzGerald P., Parkes K. R., The Cognitive Failures Questionnaire (CFQ) and its correlates, 10.1111/j.2044-8260.1982.tb01421.x
  44. EuroQol - a new facility for the measurement of health-related quality of life, 10.1016/0168-8510(90)90421-9
  45. Herdman M., Gudex C., Lloyd A., Janssen MF., Kind P., Parkin D., Bonsel G., Badia X., Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L), 10.1007/s11136-011-9903-x
  46. Janssen M. F., Pickard A. Simon, Golicki Dominik, Gudex Claire, Niewada Maciej, Scalone Luciana, Swinburn Paul, Busschbach Jan, Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study, 10.1007/s11136-012-0322-4
  47. Robine J.-M., Jagger C., , Creating a coherent set of indicators to monitor health across Europe: the Euro-REVES 2 project, 10.1093/eurpub/13.suppl_3.6
  48. van Oyen Herman, Van der Heyden Johan, Perenboom Rom, Jagger Carol, Monitoring population disability: evaluation of a new Global Activity Limitation Indicator (GALI), 10.1007/s00038-006-0035-y
  49. Berger Nicolas, Van Oyen Herman, Cambois Emmanuelle, Fouweather Tony, Jagger Carol, Nusselder Wilma, Robine Jean-Marie, Assessing the validity of the Global Activity Limitation Indicator in fourteen European countries, 10.1186/1471-2288-15-1
  50. Gisle L. Santé mentale. Dans : Van der Heyden J, Charafeddine R (éd.). Enquête de santé 2013. Rapport 1 : Santé et Bien-être. WIV-ISP, Bruxelles. 2014. . Accessed 27 Apr 2017.
  51. Drieskens S. Douleur physique. Dans : Van der Heyden J, Charafeddine R (éd.). Enquête de santé 2013. Rapport 1 : Santé et Bien-être. WIV-ISP, Bruxelles. 2014. . Accessed 27 Apr 2017.
  52. Charafeddine R. Qualité de vie liée à la santé. Dans : Van der Heyden J, Charafeddine R (éd.). Enquête de santé 2013. Rapport 1 : Santé et Bien-être. WIV-ISP, Bruxelles. 2014. . Accessed 27 Apr 2017.
  53. Tafforeau J. Santé subjective. Dans : Van der Heyden J, Charafeddine R (éd.). Enquête de santé 2013. Rapport 1 : Santé et Bien-être. WIV-ISP, Bruxelles. 2014. . Accessed 27 Apr 2017.
  54. Ponds R, van Boxtel M, Jolles J. De "cognitive failure questionnaire" als maat voor subjectief functioneren. Tijdschrift voor neuropsychologie. 2006;1(2):37–42.
  55. Jahfari Setareh, Hofhuis Agnetha, Fonville Manoj, van der Giessen Joke, van Pelt Wilfrid, Sprong Hein, Molecular Detection of Tick-Borne Pathogens in Humans with Tick Bites and Erythema Migrans, in the Netherlands, 10.1371/journal.pntd.0005042
  56. Devleesschauwer Brecht, Havelaar Arie H., Maertens de Noordhout Charline, Haagsma Juanita A., Praet Nicolas, Dorny Pierre, Duchateau Luc, Torgerson Paul R., Van Oyen Herman, Speybroeck Niko, Calculating disability-adjusted life years to quantify burden of disease, 10.1007/s00038-014-0552-z
  57. Devleesschauwer Brecht, Havelaar Arie H., Maertens de Noordhout Charline, Haagsma Juanita A., Praet Nicolas, Dorny Pierre, Duchateau Luc, Torgerson Paul R., Van Oyen Herman, Speybroeck Niko, DALY calculation in practice: a stepwise approach, 10.1007/s00038-014-0553-y
  58. Murray CJ. Quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull World Health Organ. 1994;72:429–45.
  59. The EuroQol Group. EQ-5D-5L user guide. 2015. . Accessed 9 June 2017.
  60. van Hout Ben, Janssen M.F., Feng You-Shan, Kohlmann Thomas, Busschbach Jan, Golicki Dominik, Lloyd Andrew, Scalone Luciana, Kind Paul, Pickard A. Simon, Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value Sets, 10.1016/j.jval.2012.02.008
  61. Cleemput Irina, A social preference valuations set for EQ-5D health states in Flanders, Belgium, 10.1007/s10198-009-0167-0
  62. Maertens de Noordhout C., Devleesschauwer B., Gielens L., Plasmans M. H. D., Haagsma J. A., Speybroeck N., Mapping EQ-5D utilities to GBD 2010 and GBD 2013 disability weights: results of two pilot studies in Belgium, 10.1186/s13690-017-0174-z
  63. Bilcke Joke, Hens Niel, Beutels Philippe, Quality-of-life: a many-splendored thing? Belgian population norms and 34 potential determinants explored by beta regression, 10.1007/s11136-017-1556-y
  64. R Core Team. R: A language and environment for statistical computing. 2015. R Foundation for Statistical Computing . Accessed 26 Sept 2016.
  65. McNutt L.-A., Estimating the Relative Risk in Cohort Studies and Clinical Trials of Common Outcomes, 10.1093/aje/kwg074
  66. Brecht Devleesschauwer, Scott McDonald, Juanita Haagsma, Nicolas Praet, Arie Havelaar, Niko Speybroeck. DALY: DALY Calculator - A GUI for stochastic DALY calculation in R. 2014. . Accessed 26 Sept 2016.
  67. Kretzschmar Mirjam, Mangen Marie-Josée J., Pinheiro Paulo, Jahn Beate, Fèvre Eric M., Longhi Silvia, Lai Taavi, Havelaar Arie H., Stein Claudia, Cassini Alessandro, Kramarz Piotr, , New Methodology for Estimating the Burden of Infectious Diseases in Europe, 10.1371/journal.pmed.1001205
  68. van Lier Alies, McDonald Scott A., Bouwknegt Martijn, Kretzschmar Mirjam E., Havelaar Arie H., Mangen Marie-Josée J., Wallinga Jacco, de Melker Hester E., , Disease Burden of 32 Infectious Diseases in the Netherlands, 2007-2011, 10.1371/journal.pone.0153106
  69. van den Wijngaard CC, Hofhuis A, Harms MG, Haagsma JA, Wong A, de Wit GA, et al. The burden of Lyme borreliosis expressed in disability-adjusted life years. Eur J Pub Health. 2015;
  70. Henningsson A.J., Malmvall B.-E., Ernerudh J., Matussek A., Forsberg P., Neuroborreliosis—an epidemiological, clinical and healthcare cost study from an endemic area in the south-east of Sweden, 10.1111/j.1469-0691.2009.03059.x
  71. Müller I., Freitag M. H., Poggensee G., Scharnetzky E., Straube E., Schoerner Ch., Hlobil H., Hagedorn H.-J., Stanek G., Schubert-Unkmeir A., Norris D. E., Gensichen J., Hunfeld K.-P., Evaluating Frequency, Diagnostic Quality, and Cost of Lyme Borreliosis Testing in Germany: A Retrospective Model Analysis, 10.1155/2012/595427
  72. Lohr B., Müller I., Mai M., Norris D.E., Schöffski O., Hunfeld K.-P., Epidemiology and cost of hospital care for Lyme borreliosis in Germany: Lessons from a health care utilization database analysis, 10.1016/j.ttbdis.2014.09.004
  73. Joss A.W.L., Davidson M.M., Ho-Yen D.O., Ludbrook A., Lyme disease—what is the cost for Scotland?, 10.1016/s0033-3506(03)00067-2
  74. Zhang Xinzhi, Meltzer Martin I., Peña César A., Hopkins Annette B., Wroth Lane, Fix Alan D., Economic Impact of Lyme Disease, 10.3201/eid1204.050602